AlphaCentric Advisors’s Eli Lilly LLY Stock Holding History

AlphaCentric Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.6K	Buy	48 +2	+4%	+$2.04K	0.05%	254
2026 Q1	$42.3K	Buy	+46	New	+$46.6K	0.04%	244
2024 Q4	$4.74M	Buy	+6,140	New	+$5.08M	4.73%	1
2021 Q2	–	Sell	-283	Closed	-$53K	–	231
2021 Q1	$53K	Sell	283 -9	-3%	-$1.76K	0.02%	186
2020 Q4	$49K	Sell	292 -24	-8%	-$3.58K	0.02%	183
2020 Q3	$47K	Sell	316 -28	-8%	-$4.33K	0.02%	111
2020 Q2	$56K	Buy	+344	New	+$52.8K	0.03%	78

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCentric Advisors's LLY Position: Q2 2026 in Review

AlphaCentric Advisors increased its Eli Lilly (LLY) stake by 4.3% in Q2 2026, buying an estimated $2.04K and bringing the position to 48 shares worth $57.6K. The position accounts for 0.05% of the portfolio, ranked #254.

AlphaCentric Advisors first reported a position in LLY in Q2 2020 and has held it in 7 quarters since. The position peaked at $4.74M in Q4 2024. 4,598 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

AlphaCentric Advisors held 48 shares of Eli Lilly worth $57.6K as of Q2 2026.
AlphaCentric Advisors bought 2 Eli Lilly shares in Q2 2026, an estimated $2.04K.
Eli Lilly made up 0.05% of AlphaCentric Advisors's portfolio in Q2 2026, its #254 holding.
AlphaCentric Advisors first reported a position in Eli Lilly in Q2 2020 and has held it in 7 quarters since.
AlphaCentric Advisors's Eli Lilly position peaked at $4.74M in Q4 2024.
4,598 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.